A randomized controlled trial of the effect of febuxostat treatment on and marker endothelial dysfunction and renal progression in patients with chronic kidney disease
Phase 4
Completed
- Conditions
- the effect of oral febuxostat on renal function and markers of endothelial dysfunction in CKD patients.Febuxostatasymptomatic hyperuricemiaasymmetric dimethylargininekidney disease
- Registration Number
- TCTR20210224005
- Lead Sponsor
- /A
- Brief Summary
o significant difference in the changes in serum ADMA, hsCRP, eGFR and albuminuria, was identified between the two groups. Subgroup analysis in patients with decline serum uric acid more than 2 mg/dL after febuxostat, mean eGFR in the febuxostat group showed a significant increase 2.01 mL/min/1.73/m2
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
CKD stage III-IV
serum uric > 7 mg/d
Exclusion Criteria
Treated with PZA, ethambutol, mercaptopurine, AZA, and theophylline
Hypersensitivity to febuxostat
Established cardiovascular disease
Severe hepatic impairment
Organ transplant recipients
Pregnancy and breast feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method serum asymmetric dimethylarginine (ADMA) 8 weeks level of serum asymmetric dimethylarginine (ADMA)
- Secondary Outcome Measures
Name Time Method eGFR 8 weeks level of eGFR